Clinical Study

Quantitative Relationships between Pulmonary Function and Residual Neuromuscular Blockade

ShuYing Fu,1,2,3 WenDong Lin,1,2,4 XiNing Zhao,1,2 ShengJin Ge,1,2 and ZhangGang Xue1,2

1Department of Anesthesia, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2Department of Anesthesiology, Shanghai Medical College, Fudan University, Shanghai 200032, China
3Department of Anesthesiology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325000, China
4Department of Anesthesia, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China

Correspondence should be addressed to ShengJin Ge; ge.shengjin@fudan.edu.cn

Received 28 September 2017; Revised 9 January 2018; Accepted 23 January 2018; Published 15 February 2018

Academic Editor: Robin Vos

Copyright © 2018 ShuYing Fu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Neuromuscular blockade is a risk factor for postoperative respiratory weakness during the immediate postoperative period. The quantitative relationships between postoperative pulmonary-function impairment and residual neuromuscular blockade are unknown.

Methods. 113 patients who underwent elective laparoscopic cholecystectomy were enrolled in this study. They all had a pulmonary-function test (PFT) during the preoperative evaluation. Predictive values based on demographic data were also recorded. The train-of-four ratio (TOFR) was recorded at the same time as the PFT and at every 5 minutes in the qualified 98 patients in the postanesthesia care unit (PACU). We analyzed the degree of PFT recovery when the TOFR had recovered to different degrees.

Results. There was a significant difference (P < 0.05) between the preoperative baseline value and the postoperative forced vital capacity at each TOFR point, except at a TOFR value of 1.1. There was also a significant difference (P < 0.05) between the preoperative baseline value and the postoperative peak expiratory flow at each TOFR point.

Conclusions. Postoperative residual neuromuscular blockade was common (75.51%) after tracheal extubation, and pulmonary function could not recover to an acceptable level (85% of baseline value), even if TOFR had recovered to 0.90.

Trial Registration. Chinese Clinical Trial Register is ChiCTR-OOC-15005838.

1. Introduction

Muscle relaxants are widely used in clinical practice to achieve surgical relaxation and to facilitate mechanical ventilation. The clinical objective is for complete recovery from neuromuscular blockade to occur by the time of tracheal extubation. However, on time and complete neuromuscular recovery rarely occurs, even when short- or intermediate-action muscle relaxants, and their reversal agents, are used. This condition may have negative effects on postoperative respiratory function [1].

Various factors are associated with postoperative respiratory function impairment (e.g., patient obesity, surgical incision site, and residual anesthetic agents). Residual neuromuscular blockade (RNMB) is a risk factor for postoperative respiratory weakness during the immediate postoperative period [2, 3]. Pulmonary-function impairment occurs with specific train-of-four ratio (TOFR) values or with RNMB (defined as TOFR < 0.90) [4–6]. However, the quantitative relationships between postoperative pulmonary-function impairment and RNMB are unknown. In this study, we investigated the quantitative relationships between the two variables.

2. Materials and Methods

2.1. Patient Selection. The study population consisted of patients who underwent elective laparoscopic cholecystectomy at Zhongshan Hospital, Fudan University (Shanghai, China), during 1 February 2015 to 31 May 2015. The study
protocol was approved by the Hospital's Ethics Committee (B2014-137) and registered with http://www.chictr.org.cn/: ChiCTR-OOC-15005838. Each patient who participated in the study provided his or her written informed consent.

Inclusion criteria included patients of both genders, 18 to 60 years of age, American Society of Anesthesiologists (ASA) physical status I or II, body mass index (BMI) 20 to 25 kg/m², and who received elective laparoscopic cholecystectomy under general anesthesia. The exclusion criteria included patients with cardiopulmonary dysfunction (e.g., bronchial asthma, chronic obstructive pulmonary disease, and restrictive pulmonary disease), liver or kidney dysfunction, thoracic deformity, and neuromuscular diseases. Patients with a core temperature <36°C in the postanesthesia care unit (PACU) and who were reluctant to undertake the pulmonary-function test (PFT) were excluded during the study period.

2.2. Data Collection. During the preoperative evaluation, all participants were familiarized with and underwent a PFT using a spirometer (CareFusion Microlab Jaeger Germany). Three consecutive PFTs with the patient's back reclined at 45° and the knees flexed at 20° to 30° were performed. The highest values for forced vital capacity (FVC) and peak expiratory flow (PEF) were recorded as the baseline PFT result. The predictive values of FVC and PEF, which were calculated using the spirometer result and demographic information, were also recorded. Patients were informed about the discomfort and pain, or both, associated with train-of-four (TOF) measurement (using a TOF-Watch® SX neuromuscular transmission monitor) and the additional TOF measurement (using a TOF-Watch SX neuromuscular transmission monitor) and the additional PFT that would be performed once during the postoperative period. None of the patients were given premedications.

Standard intraoperative monitoring included electrocardiography (ECG), noninvasive blood pressure (NIBP), pulse oximetry (SpO₂), and end-tidal carbon dioxide (ETCO₂) in the operating room. Anesthesia was induced using intravenous anesthetics, including a propofol target-controlled infusion to a plasma concentration of 4 μg/ml⁻¹. Intravenous remifentanil (0.2 μg·kg⁻¹·min⁻¹), fentanyl (2.0–2.5 μg·kg⁻¹), rocuronium (0.6 mg·kg⁻¹), and lidocaine (1mg·kg⁻¹) were also given. Rocuronium was the unique nondepolarizing agent used for muscle relaxation. Neuromuscular monitoring was not performed during the intraoperative period.

Anesthesia was maintained using intravenous or intravenous compound inhalation anesthesia. A propofol infusion was used for intravenous anesthesia and a sevoflurane inhaled compound propofol infusion was used for compound anesthesia. Fentanyl and rocuronium were infused based on each patient's condition during the intraoperative period. All patients were given flurbiprofen axetil (50 mg) for postoperative pain relief and tropisetron (6 mg) for antiemesis, before wound closure. The anesthesiologists in charge decided whether to reverse neuromuscular function with neostigmine and the extubation time based on clinical signs. The patients were transported into the PACU after extubation.

During postoperative recovery in the PACU, all patients were continuously monitored (ECG, NIBP, SpO₂), received 5 L/min oxygen via a mask, and were covered with a blanket. The ear temperature of each patient enrolled in the study was measured at arrival to the PACU. Patients with a temperature <36°C were excluded from the study. The TOF-Watch SX was used to immediately test the degree of RNMB (four 0.2 ms pulses at a 2 Hz frequency and 50 mA current intensity at 15 s time interval). The TOF measurement was repeated three times, and the mean value of the consecutive measurements was recorded. Patients were also checked every 5 min to determine whether they were awake or in pain, had nausea or vomiting, and were willing to perform the PFT. When the patient was willing to perform the test, three consecutive PFT measurements were obtained with the patient's back reclined at 45° and the knees flexed 20° to 30°; the highest of the three values was recorded. If the patient was willing to perform the PFT when TOFR was being measured, PFT measurements were recorded concurrently with TOFR measurements until the patient was discharged from the PACU.

2.3. Statistical Analysis. The statistical analysis was performed using IBM SPSS Statistics 19.0 for Windows software (IBM Corp, Armonk, NY). We used the data pairs of TOFR and pulmonary-function values obtained from the PFTs performed at the same time-points during which the TOFRs were measured. We grouped the data pairs into 0.10 intervals, according to the TOFR values. TOFR neuromuscular function was achieved when the recovery point reached an accelerometer measurement value of 0.4 (i.e., 0.40–0.49 range). The other values for each range were 0.5 (0.50–0.59), 0.60 (0.60–0.69), 0.7 (0.70–0.79), 0.80 (0.80–0.89), 0.9 (0.90–0.99), 1.00 (1.00–1.09), and 1.1 (1.10–1.19). We then analyzed the differences in pulmonary function at different TOFR neuromuscular function recovery points. Patients were divided into two groups, RNMB-absent (TOFR ≥ 0.90) and RNMB-present (TOFR < 0.90) based on the TOFR at the first time the PFT was performed. We analyzed the differences between the RNMB-absent and RNMB-present groups to examine the factors that affect RNMB blockade.

Enumerated data were compared using Fisher exact test or chi-square test, as appropriate. Comparison of continuous variables among the groups was performed using one-way analysis of variance with post hoc Bonferroni or Games-Howell tests; if the data are heterogeneity of variance, Kruskal-Wallis test was used. Paired-samples t-tests analyzed data within one group. Probability values < 0.05 were indicative of statistically significant differences.

3. Results

A total of 113 patients met the inclusion criteria and provided informed consent. Fifteen of these patients were excluded from the study because of pain, nausea, vomiting, a low body temperature, or unwillingness to perform the PFT in the PACU. Ninety-eight patients were identified as the final group of participants. These patients did not have a body temperature <36°C, pain (VSA score ≥ 3), nausea, vomiting, or an SpO₂ < 98%; they also cooperated willingly with the PFT.

Summary of results for study variables is shown in Table 1. On arrival to the PACU, the mean TOFR was 0.75 ± 0.21; 27.55% (27/98) of the patients had a TOFR < 0.70, and 75.51%
Table 1: Summary of results for study variables.

|                  | Values                          |
|------------------|---------------------------------|
| Gender (male/female) | 38/60                           |
| Age, yrs         | 48.96 ± 11.22                   |
| BMI (kg/m²)      | 23.57 ± 2.34                    |
| Preoperative FVC (L) | 2.92 ± 0.79                     |
| Preoperative PEF (L/s) | 6.19 ± 1.87                     |
| Ratio of using PCIA | 56.12% (55/98)                  |
| Ratio of using muscle relaxant antagonist | 69.39% (68/98)                  |
| Anesthesia time (min) | 76.89 ± 24.14                   |
| Total dose of rocuronium (mg) | 43.98 ± 7.28                   |
| Total dose of fentanyl (µg) | 231.12 ± 59.97                  |

At the first time willing to perform PFT

| TOFR | Number of data pairs | Postoperative FVC (L) | Postoperative PEF (L/s) | Recovery ratio of postoperative FVC to basic values | Recovery ratio of postoperative PEF to basic values | Recovery ratio of postoperative FVC to predicted values | Recovery ratio of postoperative PEF to predicted values |
|------|----------------------|-----------------------|------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| 0.4  | 4                    | 1.61 ± 0.42           | 3.03 ± 0.80            | 0.61 ± 0.07                                    | 0.53 ± 0.08                                    | 0.45 ± 0.07                                      | 0.42 ± 0.08                                      |
| 0.5  | 9                    | 1.83 ± 0.41           | 3.04 ± 0.49            | 0.63 ± 0.11                                    | 0.59 ± 0.10                                    | 0.56 ± 0.05                                      | 0.47 ± 0.08                                      |
| 0.6  | 19                   | 2.01 ± 0.48           | 3.80 ± 1.21            | 0.70 ± 0.17                                    | 0.60 ± 0.17                                    | 0.59 ± 0.12                                      | 0.52 ± 0.14                                      |
| 0.7  | 48                   | 2.27 ± 0.56           | 4.26 ± 1.45            | 0.76 ± 0.10                                    | 0.65 ± 0.15                                    | 0.63 ± 0.11                                      | 0.57 ± 0.13                                      |
| 0.8  | 166                  | 2.30 ± 0.57           | 4.30 ± 1.36            | 0.79 ± 0.12                                    | 0.69 ± 0.12                                    | 0.65 ± 0.13                                      | 0.59 ± 0.15                                      |
| 0.9  | 211                  | 2.32 ± 0.66           | 4.32 ± 1.36            | 0.83 ± 0.11                                    | 0.72 ± 0.16                                    | 0.66 ± 0.14                                      | 0.60 ± 0.15                                      |
| 1.0  | 105                  | 2.44 ± 0.64           | 4.55 ± 1.44            | 0.84 ± 0.11                                    | 0.74 ± 0.17                                    | 0.71 ± 0.12                                      | 0.64 ± 0.15                                      |
| 1.1  | 18                   | 2.98 ± 0.54           | 5.00 ± 1.10            | 0.86 ± 0.09                                    | 0.77 ± 0.13                                    | 0.73 ± 0.07                                      | 0.65 ± 0.12                                      |

Table 2: Postoperative pulmonary function and recovery ratio values at different TOFR neuromuscular function recovery points.

4. Discussion

4.1. Postoperative Residual Neuromuscular Blockade. The review of Murphy and Brull [7] revealed that the incidence of RNMB varies from 3.5% to 88%. The meta-analysis of Naguib et al. [8] indicated that the incidence of RNMB is much higher when the TOFR is set as <0.9 and that this value is a more useful diagnostic criterion than a TOFR < 0.7. The incidence of RNMB was also very high in our study population; 27.55% (27/98) of patients had a TOFR < 0.70, and 75.51% (74/98) of them had a TOFR < 0.90 on arrival to the PACU. The patient’s age, gender, height, weight, and perioperative conditions may affect neuromuscular function recovery. Postoperative RNMB is more frequent in the elderly (44%) compared with younger (20%) patients [9]. Spontaneous and neostigmine-assisted neuromuscular function recovery is more rapid in children than in adults [10]. Adamus et al. [11]
proposed that females are more sensitive to rocuronium. Fujimoto et al. [12] reported that drug pharmacokinetics and pharmacodynamics change in obese patients; muscle relaxation time is significantly prolonged when the drug is administered based on body weight. Wang et al. [13] found that retransfusion of salvaged blood significantly impairs neuromuscular function recovery in the PACU. Teng et al. [14] reported that an elevated PaCO₂ prolongs spontaneous recovery of the neuromuscular blockade induced by rocuronium. Our study results indicated that age, gender, BMI, preoperative pulmonary function, anesthesia maintenance time, dosage of fentanyl, and ratio of PCIA between the RNMB-present and RNMB-absent groups were similar, and only the dosage of rocuronium and the ratio of given muscle relaxant antagonist between the two groups were significantly different. That can be explained by our strict inclusion criteria: 18 to 60 years of age, ASA physical status I or II, BMI 20–25 kg/m², and receiving elective laparoscopic cholecystectomy under general anesthesia.

Postoperative pulmonary-function impairment occurred in almost every patient who underwent general anesthesia, especially in patients with RNMB, and other factors include surgical method, artificial pneumoperitoneum, mechanical ventilation, and incomplete metabolism of opioids [2, 15]. Although in PACU no patient had dyspnea, hypoxemia, upper airway obstruction, or bronchial spasm, in our study, they were already exposed to the well-described risks of RNMB.

RNMB can cause airway dysfunction, and impairment of the coordination of pharyngeal and upper esophageal muscles [15]; these conditions can result in airway obstruction, aspiration pneumonia, respiratory failure, bronchospasm, hypoxemia, atelectasis, and other severe postoperative pulmonary complications postoperatively in PACU and/or in the ward. Xara et al. found [16] that RNMB is an independent risk factor for adverse respiratory events in the PACU. Asai and Isono [17] concluded that RNMB after anesthesia is a cause of postoperative aspiration pneumonia. Eikermann et al. [6] found that coordination of upper respiratory muscles was suppressed when neuromuscular function was blocked, even if there were no obvious signs of respiratory insufficiency. Sundman et al. [18] found that partial neuromuscular paralysis is associated with a 4- to 5-fold increase in the incidence of misdirected swallowing. The mechanism of the pharyngeal dysfunction is the delay of the swallowing reflex, which results from the pharyngeal muscle function impairment. Piccioni et al. [19] reported that RNMB in healthy elderly individuals may cause an increased incidence of pharyngeal dysfunction (from 37 to 71%) and impairment of pharyngeal protection of the airway.

Under normal circumstances, pulmonary ventilation increases to reverse hypoxemia and hypercapnia. This response is a protective reflex. In hypoxicemic conditions, the RNMB caused by a nondepolarizing muscle relaxant can reduce the sensitivity of the carotid body chemoreceptor and impair the hypoxic ventilation reflex [20].

| Table 3: Comparison of residual neuromuscular blockade- (RNMB-) present and RNMB-absent groups. |
|---------------------------------------------------------------|
| Age, yrs | RNMB-present (n = 64) | RNMB-absent (n = 34) | P value |
| Gender (male/female) | 48.52 ± 10.67 | 49.79 ± 12.30 | 0.296 |
| BMI (kg/m²) | 22/42 | 16/18 | 0.220 |
| Anesthesia time (min) | 23.59 ± 2.43 | 23.52 ± 2.18 | 0.462 |
| Total dose of fentanyl (µg) | 78.20 ± 24.26 | 74.41 ± 24.08 | 0.462 |
| Total dose of rocuronium (mg) | 235.94 ± 65.29 | 222.06 ± 47.98 | 0.278 |
| Ratio of not using muscle relaxant antagonist | 45.30 ± 7.63 | 41.32 ± 5.81 | 0.008 |
| Ratio of using PCIA (yes/no) | 35/29 | 20/14 | 0.695 |
| Preoperative FVC (L) | 42.19% (27/64) | 8.82% (3/34) | 0.001 |
| Preoperative PEF (L/s) | 6.12 ± 1.72 | 6.33 ± 2.16 | 0.257 |

RNMB, residual neuromuscular blockade; BMI, body mass index; FVC, forced vital capacity; PEF, peak expiratory flow; PCIA, patient-controlled intravenous analgesia; TOFR, train-of-four ratio; PFT, pulmonary-function test; PACU, postanesthesia care unit.
study, there was a significant reduction in the postoperative
FVC and PEF values compared with the baseline values
(i.e., the greater the RNMB, the greater the reduction).
There was a significant difference \( P < 0.05 \) between the
preoperative baseline value and the postoperative FVC at
each TOFR point, except at TOFR 1.1. There was also a
significant difference \( P < 0.05 \) between the preoperative
baseline value and the postoperative PEF at each TOFR
point. The study of Kumar et al. \[4\] results suggested that
postoperative pulmonary-function recovery to 85% of the
preoperative base value is an acceptable level. In our study,
only when TOFR had recovered to more than 1.1, the FVC
\((0.86 \pm 0.09)\) of preoperative baseline value) could achieve an
acceptable level. This may indicate that pulmonary function
could not yet return to an acceptable level even though the
values obtained during TOFR monitoring of neuromuscular
function has recovered to an acceptable level of 0.9.

Our study had some limitations. Firstly, all patients were
extubated under the decision of experienced anesthesiolo-
gists, and the PFT was performed when the patient was
awake and willing to take the test. So, among the 580 data
pairs of TOFR and pulmonary-function values, there were
only 32 data pairs of TOFR < 0.7. As a result, we could not
analyze accurately the correlation of TOFR and pulmonary
function. Secondly, the subjects in this study were quite
"normal": 18 to 60 years of age, ASA physical status I or
II, BMI 20–25 kg/m\(^2\), and receiving elective laparoscopic
cholecystectomy (less traumatic). Then, the results may not
analyze accurately the correlation of TOFR and pulmonary
function. Therefore, we could not fully analyze the data
for those patients who had a BMI greater than 25 kg/m\(^2\).

5. Conclusion

Our study included a quantitative analysis between postop-
erative pulmonary function and RNMB. We found that a
higher ratio of postoperative RNMB was common (75.51%)
after tracheal extubation, and pulmonary function had not
recovered to an acceptable level (85% of baseline values), even
if TOFR had recovered to 0.90.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This work is supported by special clinical medicine research
fund of The Chinese Medical Association (no. 13081340519).

References

[1] G. S. Murphy, J. W. Szokol, J. H. Marymont, M. Franklin, M.
J. Avram, and J. S. Vender, "Residual paralysis at the time of
tracheal extubation," Anesthesia & Analgesia, vol. 100, no. 6,
p. 1840–1845, 2005.

[2] G. S. Murphy, J. W. Szokol, J. H. Marymont, S. B. Greenberg, M.
J. Avram, and J. S. Vender, "Residual neuromuscular blockade
and critical respiratory events in the postanesthesia care unit,"
Anesthesia & Analgesia, vol. 107, no. 1, pp. 130–137, 2008.

[3] H. Berg, J. Viby-Mogensen, J. Roed et al., “Residual neu-omuscular block is a risk factor for postoperative pulmonary
complications—a prospective, randomised, and blinded study
of postoperative pulmonary complications after atracurium,
vecuronium and pancuronium,” Acta Anaesthesiologica Scandi-
avica, vol. 41, no. 9, pp. 1095–1103, 1997.

[4] G. V. Kumar, A. P. Nair, H. S. Murthy, K. R. Jalaja, K. Ramachan-
dra, and G. Parameshwara, "Residual neuromuscular blockade
affects postoperative pulmonary function," Anesthesiology, vol.
117, no. 6, pp. 1234–1244, 2012.

[5] M. Eikermann, H. Groeben, J. Hüsing, and J. Peters, “Accelerom-
etry of adductor pollicis muscle predicts recovery of respi-
atory function from neuromuscular blockade,” Anesthesiology,
vol. 98, no. 6, pp. 1333–1337, 2003.

[6] M. Eikermann, H. Groeben, B. Bünten, and J. Peters, “Fade of
pulmonary function during residual neuromuscular blockade,”
Chest, vol. 127, no. 5, pp. 1703–1709, 2005.

[7] G. S. Murphy and S. J. Brull, "Residual neuromuscular block:
lessons unlearned. Part I: definitions, incidence, and adverse
physiologic effects of residual neuromuscular block," Anesthesia
& Analgesia, vol. 111, no. 1, pp. 120–128, 2010.

[8] M. Naguib, A. F. Kopman, and J. E. Ensor, "Neuromuscular
monitoring and postoperative residual curarisation: a meta-
analysis," British Journal of Anaesthesia, vol. 98, no. 3, pp. 302–
316, 2007.

[9] P. Pietraszewski and T. Gaszyński, “Residual neuromuscular
block in elderly patients after surgical procedures under general
anaesthesia with rocuronium,” Anesthesiology Intensive Ther-
apy, vol. 45, no. 2, pp. 77–81, 2013.

[10] J. C. Bevan, L. Collins, C. Fowler et al., “Early and late reversal
of rocuronium and vecuronium with neostigmine in adults and
children,” Anesthesia & Analgesia, vol. 89, no. 2, pp. 333–339,
1999.

[11] M. Adamus, L. Hrabalek, T. Wanek, T. Gabrhelik, and J. Zaple-
talova, “Influence of age and gender on the pharmacodynamic
parameters of rocuronium during total intravenous anesthesia,”
Biomedical Papers, vol. 155, no. 4, pp. 347–353, 2011.

[12] M. Fujimoto, C. Tanahira, M. Nishi, and T. Yamamoto, “In non-
obese patients, duration of action of rocuronium is directly cor-
related with body mass index,” Canadian Journal of Anesthesia,
vol. 60, no. 6, pp. 552–556, 2013.

[13] G. Wang, J. Wang, H. Zhou, X. Zhao, and X. Wu, “Impairment
of recovery of muscle function by residual rocuronium after re-
transfusion of intraoperative salvaged blood,” Chinese Medical
Journal, vol. 127, pp. 821–824, 2014.

[14] L. Teng, L. Chen, H. Ma, Y. Zhou, and S. Li, “Effects of arterial
carbon dioxide on recovery from rocuronium-induced neuro-
 muscular blockade in anesthetized patients,” Asian Biomedicine,
v. 7, pp. 73–79, 2013.

[15] A. Miskovic and A. B. Lumb, “Postoperative pulmonary com-
 plications,” British Journal of Anaesthesia, vol. 118, no. 3, pp. 317–
334, 2017.

[16] D. Xara, A. Santos, and F. Abela, “Adverse respiratory events in
a post-anesthesia care unit,” Archives de Bronconeumología, vol.
51, no. 2, pp. 69–75, 2015.

[17] T. Asai and S. Isono, "Residual neuromuscular blockade
after anesthesia: A possible cause of postoperative aspiration-
induced pneumonia," Anesthesiology, vol. 120, no. 2, pp. 260–
262, 2014.
[18] E. Sundman, H. Witt, R. Olsson, O. Ekberg, R. Kuylestierna, and L. I. Eriksson, “The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium,” *Anesthesiology*, vol. 92, no. 4, pp. 977–984, 2000.

[19] F. Piccioni, L. Mariani, L. Bogno et al., “An acceleromyographic train-of-four ratio of 1.0 reliably excludes respiratory muscle weakness after major abdominal surgery: A randomized double-blind study,” *Canadian Journal of Anesthesia*, vol. 61, no. 7, pp. 641–649, 2014.

[20] A. Igarashi, S. Amagasa, H. Horikawa, and M. Shirahata, “Vecuronium directly inhibits hypoxic neurotransmission of the rat carotid body,” *Anesthesia & Analgesia*, vol. 94, no. 1, pp. 117–122, 2002.